Evidence map›Paper›PMID 36101793›Full record

Observational studyInternational journal of chronic obstructive pulmonary disease2022

Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain.

Victoria Neches García, Laura Amanda Vallejo-Aparicio, Afisi S Ismaila, Antoni Sicras-Mainar, Aram Sicras-Navarro, Cruz González, Rafael Cuervo, Soham Shukla, Marcos García-Peñuela

Abstract readObservational Study
In one paragraph

Observational study in International journal of chronic obstructive pulmonary disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Victoria Neches GarcíaMarket Access, GlaxoSmithKline, Madrid, Spain.ORCID 0000-0003-1149-5830
Laura Amanda Vallejo-AparicioMarket Access, GlaxoSmithKline, Madrid, Spain.ORCID 0000-0002-8579-0835
Afisi S IsmailaValue Evidence and Outcomes, GlaxoSmithKline, Collegeville, PA, USA.ORCID 0000-0002-2876-8308
Antoni Sicras-MainarReal Life Data, Atrys Health, Barcelona, Spain.ORCID 0000-0002-8232-293X
Aram Sicras-NavarroReal Life Data, Atrys Health, Barcelona, Spain.ORCID 0000-0002-0269-0354
Cruz GonzálezPneumology Unit, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Rafael CuervoMedical Affairs, GlaxoSmithKline, Madrid, Spain.ORCID 0000-0002-3522-486X
Soham ShuklaValue Evidence and Outcomes, GlaxoSmithKline, Collegeville, PA, USA.ORCID 0000-0002-4139-0856
Marcos García-PeñuelaMedical Affairs, GlaxoSmithKline, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To determine the clinical and economic impact of inhaled corticosteroid (ICS) withdrawal in Spanish patients with COPD receiving triple therapy (TT) with ICS, long-acting β Patients and Methods: This was an observational, retrospective study of BIG-PAC database medical records. Patients aged ≥40 years receiving TT from 2016 to 2018 were followed for 1 year. Two cohorts were identified: patients continuing TT (ICS+LABA+LAMA), and patients receiving TT with ICS withdrawn (LABA+LAMA). Variables included medication, exacerbations (moderate and severe), pneumonia, mortality, health resource use (HRU), and cost per patient/year. Cohorts were compared using propensity score matching (PSM). Multivariate statistical analysis using analysis of covariance and Cox proportional risks was conducted. Results: Of 6541 patients included, 5740 (87.8%) continued TT and 801 (12.2%) had ICS withdrawn. Patients with ICS withdrawal were younger, had lower disease burden, higher ICS doses, and more exacerbations compared with those continuing ICS. PSM matched 795 patients in each cohort. Mean age was 68.5 years (SD: 11.2), 69.9% were male, and mean Charlson index was 2.0. Patients with ICS withdrawal had more total exacerbations in the 12 months following withdrawal compared with patients continuing TT (36.6% vs 31.4%; p=0.030). No significant differences were found for pneumonia (3.3% vs 3.6%; p=0.583) and mortality (9.9% vs 7.5%; p=0.092). Median time to first exacerbation was shorter in patients with ICS withdrawal compared with those continuing ICS (HR: 0.69, 95% CI: 0.57-0.83; p<0.001). Mean health cost per patient/year among patients with ICS withdrawal was higher than those continuing TT (€2993 vs €2130; p<0.001). Conclusion: ICS withdrawal in patients with COPD receiving TT was associated with increased exacerbations, HRU, and costs compared with continuing TT, with health and economic impacts on patients and the Spanish National Healthcare System, respectively. Pneumonia and mortality rates were similar between groups.

Indexed as

PneumoniaPulmonary Disease, Chronic ObstructiveAdministration, InhalationAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAgedBronchodilator AgentsFemaleHumansMaleMuscarinic AntagonistsRetrospective StudiesSpainAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsMuscarinic AntagonistsCOPDexacerbationshealth costsinhaled corticosteroid withdrawalresource use

Identifiers

PMID36101793
PMCPMC9464437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.